---
{"dg-publish":true,"permalink":"/entities/supplement/omega-3-fatty-acids/","tags":["supplement","essential_fatty_acid","cardiovascular","anti_inflammatory","brain_health"]}
---

# Omega-3 Fatty Acids

## Overview
Essential polyunsaturated fatty acids (EPA and DHA) critical for cardiovascular health, brain function, and inflammation reduction. Found naturally in fatty fish and available as concentrated supplements.








## Relationships
### Affects Organ
- → [[entities/Organ/Heart\|Heart]] (organ)
```yaml
last_modified: '2025-12-28T11:01:24.114762'
source: obsidian
```
- → [[entities/Organ/Eyes\|Eyes]] (organ)
```yaml
last_modified: '2025-12-28T11:01:24.168501'
source: obsidian
```
- → [[entities/Organ/Joints\|Joints]] (organ)
```yaml
last_modified: '2025-12-28T11:01:24.195233'
source: obsidian
```
- → [[entities/Organ/Brain\|Brain]] (organ)
```yaml
last_modified: '2025-12-28T11:01:24.143491'
source: obsidian
```

### Modulates Neurotransmitter
- → [[entities/Neurotransmitter/Serotonin\|Serotonin]] (neurotransmitter)
```yaml
last_modified: '2025-12-28T11:01:24.222648'
source: obsidian
```
- → [[entities/Neurotransmitter/Dopamine\|Dopamine]] (neurotransmitter)
```yaml
last_modified: '2025-12-28T11:01:24.249170'
source: obsidian
```

### Improves Condition
- → [[Chronic_Inflammation\|Chronic_Inflammation]] (condition)
```yaml
last_modified: '2025-12-28T11:01:24.349991'
source: obsidian
```

### May Improve Condition
- → [[entities/condition/Hypertension\|Hypertension]] (condition)
```yaml
last_modified: '2025-12-28T11:01:24.377214'
source: obsidian
```
- → [[Metabolic_Syndrome\|Metabolic_Syndrome]] (condition)
```yaml
last_modified: '2025-12-28T11:01:24.404652'
source: obsidian
```
- → [[entities/phenotype/Anxiety\|Anxiety]] (phenotype)
```yaml
last_modified: '2025-12-28T11:01:24.461317'
source: obsidian
```

### Synergistic With
- ← [[entities/Supplement/Curcumin\|Curcumin]] (supplement)
```yaml
last_modified: '2025-12-28T11:01:20.437235'
source: obsidian
```
- → [[entities/Supplement/CoQ10\|CoQ10]] (supplement)
```yaml
last_modified: '2025-12-28T11:01:24.567405'
source: obsidian
```
- → [[entities/Supplement/Curcumin\|Curcumin]] (supplement)
```yaml
last_modified: '2025-12-28T11:01:24.619060'
source: obsidian
```
- ← [[Vitamin_D\|Vitamin_D]] (biomarker)
```yaml
last_modified: '2025-12-28T11:01:28.208162'
source: obsidian
```

### Related To
- → [[Keto_Diet\|Keto_Diet]] (intervention)
```yaml
last_modified: '2025-12-28T11:01:24.650561'
source: obsidian
```

### Related
- → [[entities/Hormone/Cortisol\|Cortisol]] (biomarker)
```yaml
last_modified: '2026-01-19T09:07:12.965838'
source: obsidian
```
- → [[entities/labtest/triglycerides\|Triglycerides]] (biomarker)
```yaml
last_modified: '2026-01-19T09:07:12.965838'
source: obsidian
```
- → [[Chronic_Inflammation\|Chronic_Inflammation]] (entity)
```yaml
last_modified: '2026-01-19T09:07:12.965838'
source: obsidian
```
- → [[Metabolic_Syndrome\|Metabolic_Syndrome]] (entity)
```yaml
last_modified: '2026-01-19T09:07:12.965838'
source: obsidian
```
- → [[Vitamin_D\|Vitamin_D]] (entity)
```yaml
last_modified: '2026-01-19T09:07:12.965838'
source: obsidian
```
- → [[Keto_Diet\|Keto_Diet]] (entity)
```yaml
last_modified: '2026-01-19T09:07:12.965838'
source: obsidian
```
- → [[entities/phenotype/Anxiety\|Anxiety]] (phenotype)
```yaml
last_modified: '2026-01-19T09:07:12.965838'
source: obsidian
```
- → [[entities/condition/Hypertension\|Hypertension]] (condition)
```yaml
last_modified: '2026-01-19T09:07:12.965838'
source: obsidian
```
- → [[entities/Supplement/Curcumin\|Curcumin]] (supplement)
```yaml
last_modified: '2026-01-19T09:07:12.965838'
source: obsidian
```
- → [[entities/Supplement/CoQ10\|CoQ10]] (supplement)
```yaml
last_modified: '2026-01-19T09:07:12.965838'
source: obsidian
```
- → [[entities/Organ/Brain\|Brain]] (organ)
```yaml
last_modified: '2026-01-19T09:07:12.965838'
source: obsidian
```
- → [[entities/Organ/Joints\|Joints]] (organ)
```yaml
last_modified: '2026-01-19T09:07:12.965838'
source: obsidian
```
- → [[entities/Organ/Eyes\|Eyes]] (organ)
```yaml
last_modified: '2026-01-19T09:07:12.965838'
source: obsidian
```
- → [[entities/Organ/Heart\|Heart]] (organ)
```yaml
last_modified: '2026-01-19T09:07:12.965838'
source: obsidian
```
- → [[entities/Neurotransmitter/Dopamine\|Dopamine]] (neurotransmitter)
```yaml
last_modified: '2026-01-19T09:07:12.965838'
source: obsidian
```
- → [[entities/Neurotransmitter/Serotonin\|Serotonin]] (neurotransmitter)
```yaml
last_modified: '2026-01-19T09:07:12.965838'
source: obsidian
```

### Decreases Biomarker
- → [[entities/labtest/triglycerides\|Triglycerides]] (biomarker)
```yaml
effect_direction: decreases
evidence_level: 5
last_modified: '2026-01-19T09:07:12.526277'
magnitude: strong
magnitude_range: 25-30% reduction
notes: FDA-approved for hypertriglyceridemia at 4g/day. Dose-response relationship
  well established.
onset_timeframe: 4-12 weeks
population_context: elevated triglycerides
source: obsidian
study_references:
- PMID:30586774
- PMID:31422671
```
- → [[hs-CRP\|hs-CRP]] (entity)
```yaml
effect_direction: decreases
evidence_level: 4
last_modified: '2026-01-19T09:07:12.526277'
magnitude: moderate
magnitude_range: 0.5-1.0 mg/L
notes: Anti-inflammatory via resolvin and protectin production. Effect more pronounced
  in metabolic syndrome.
onset_timeframe: 8-12 weeks
population_context: elevated inflammation
source: obsidian
study_references:
- PMID:29215416
- PMID:24505395
```
- → [[Blood_Pressure\|Blood_Pressure]] (entity)
```yaml
effect_direction: decreases
evidence_level: 3
last_modified: '2026-01-19T09:07:12.526277'
magnitude: mild
magnitude_range: 2-4 mmHg systolic
notes: Effect via improved endothelial function. More pronounced with >3g/day EPA+DHA.
onset_timeframe: 8-12 weeks
population_context: hypertensive
source: obsidian
study_references:
- PMID:24610882
- PMID:28493050
```
- → [[entities/biomarker/Vldl\|VLDL]] (entity)
```yaml
effect_direction: decreases
evidence_level: 4
last_modified: '2026-01-19T09:07:12.526277'
magnitude: moderate
magnitude_range: 20-30% reduction
notes: Reduces hepatic VLDL production. Correlates with triglyceride reduction.
onset_timeframe: 4-8 weeks
population_context: elevated triglycerides
source: obsidian
study_references:
- PMID:31422671
```

### Increases Biomarker
- → [[Omega-3_Index\|Omega-3_Index]] (entity)
```yaml
effect_direction: increases
evidence_level: 5
last_modified: '2026-01-19T09:07:12.526277'
magnitude: strong
magnitude_range: 4-8% absolute increase
notes: Direct supplementation effect. Target >8% for cardiovascular protection.
onset_timeframe: 4-8 weeks
population_context: general
source: obsidian
study_references:
- PMID:24558110
- PMID:29754316
```

### Improved By Supplement
- ← [[Cardiovascular_Risk_Pattern\|Cardiovascular_Risk_Pattern]] (clinicalpattern)
```yaml
last_modified: '2026-01-19T09:04:55.233761'
source: obsidian
```
- ← [[Kidney_Stress_Pattern\|Kidney_Stress_Pattern]] (clinicalpattern)
```yaml
last_modified: '2026-01-19T09:04:58.085415'
source: obsidian
```
- ← [[Metabolic_Syndrome\|Metabolic_Syndrome]] (condition)
```yaml
last_modified: '2026-01-19T09:04:59.412832'
source: obsidian
```